Who
Manmeet Singh Soni
Director
Company insider
Files Form 4 as: Director, Pulse Biosciences; COO and CFO, Summit Therapeutics; COO, CFO and President, Reata Pharmaceuticals; Director, Arena Pharmaceuticals; Chief Financial Officer, Alnylam Pharmaceuticals; EVP, CFO & Treasurer, Ariad Pharmaceuticals; Chief Financial Officer, Pharmacyclics.
In numbers
- Trades disclosed
- 129
- Buys
- 4
- Sells
- 14
- Bought
- $7.2M
- Sold
- $30.7M
- Companies
- 7
- Companies where not an officer
- 2
- First trade
- 30 Apr 2013
- Last trade
- 11 Jun 2026
- Last filed
- 15 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 15 Jun 2026 | PLSE Pulse Biosciencesoption or derivative · Medical Devices | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | PLSE Pulse Biosciencesoption or derivative · Medical Devices | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 4 Jun 2026filed 4 Jun 2026 | SMMT Summit TherapeuticsBiotechnology | SEC FORM 4 Bought | $362K25,000 at $14.46 | filing |
| 4 Jun 2026filed 4 Jun 2026 | SMMT Summit TherapeuticsBiotechnology | SEC FORM 4 Bought | $361K25,000 at $14.43 | filing |
| 4 Jun 2026filed 4 Jun 2026 | SMMT Summit TherapeuticsBiotechnology | SEC FORM 4 Bought | $362K25,000 at $14.46 | filing |
| 4 Jun 2026filed 4 Jun 2026 | SMMT Summit TherapeuticsBiotechnology | SEC FORM 4 Bought | $361K25,000 at $14.43 | filing |
| 21 Oct 2025filed 23 Oct 2025 | SMMT Summit TherapeuticsBiotechnology | SEC FORM 4 Code A | $1000K53,361 at $18.74 | filing |
| 15 Aug 2025filed 19 Aug 2025 | PLSE Pulse Biosciencesoption or derivative · Medical Devices | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 29 Apr 2025filed 1 May 2025 | SMMT Summit Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,200,000 | filing |
| 11 Sep 2024filed 13 Sep 2024 | SMMT Summit TherapeuticsBiotechnology | SEC FORM 4 Code A | $1000K44,052 at $22.70 | filing |
| 23 Aug 2024filed 23 Aug 2024 | SMMT Summit Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,800,000 | filing |
| 9 Aug 2024filed 13 Aug 2024 | PLSE Pulse Biosciencesoption or derivative · Medical Devices | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 6 Jun 2024filed 24 Jun 2024 | PLSE Pulse Biosciencesoption or derivative · Medical Devices | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 2 Apr 2024filed 4 Apr 2024 | SMMT Summit Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,100,000 | filing |
| 13 Oct 2023filed 16 Oct 2023 | SMMT Summit Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,000,000 | filing |
| 13 Oct 2023filed 16 Oct 2023 | SMMT Summit TherapeuticsBiotechnology | SEC FORM 4 Bought | $5.0M2,976,190 at $1.68 | filing |
| 26 Sep 2023filed 26 Sep 2023 | Reata Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —24,000 | filing |
| 26 Sep 2023filed 26 Sep 2023 | Reata Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —75,000 | filing |
| 26 Sep 2023filed 26 Sep 2023 | Reata Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —75,000 | filing |
| 26 Sep 2023filed 26 Sep 2023 | Reata Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —95,475 | filing |
News
No headline names them, or the companies they trade most, lately.